246,833 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Purchased by ExodusPoint Capital Management LP

ExodusPoint Capital Management LP purchased a new stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The fund purchased 246,833 shares of the company's stock, valued at approximately $1,812,000. ExodusPoint Capital Management LP owned about 0.18% of Vir Biotechnology as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of the business. SBI Securities Co. Ltd. purchased a new stake in Vir Biotechnology during the 4th quarter valued at $60,000. PNC Financial Services Group Inc. lifted its holdings in shares of Vir Biotechnology by 31.8% in the 4th quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company's stock worth $61,000 after acquiring an additional 1,999 shares during the last quarter. KBC Group NV boosted its stake in shares of Vir Biotechnology by 136.5% during the 4th quarter. KBC Group NV now owns 8,970 shares of the company's stock worth $66,000 after purchasing an additional 5,177 shares during the period. CIBC Asset Management Inc bought a new position in Vir Biotechnology during the 4th quarter valued at about $74,000. Finally, Virtu Financial LLC purchased a new stake in Vir Biotechnology in the 4th quarter worth about $94,000. Institutional investors own 65.32% of the company's stock.

Analyst Upgrades and Downgrades

VIR has been the subject of a number of recent analyst reports. HC Wainwright restated a "buy" rating and issued a $110.00 price target on shares of Vir Biotechnology in a report on Friday, February 28th. Leerink Partners raised their target price on shares of Vir Biotechnology from $18.00 to $20.00 and gave the company an "outperform" rating in a research note on Monday, January 13th. JPMorgan Chase & Co. increased their price target on shares of Vir Biotechnology from $10.00 to $14.00 and gave the stock a "neutral" rating in a report on Thursday, January 9th. Morgan Stanley raised shares of Vir Biotechnology from an "equal weight" rating to an "overweight" rating and upped their price target for the company from $10.00 to $20.00 in a report on Thursday, January 9th. Finally, Barclays boosted their price objective on Vir Biotechnology from $26.00 to $31.00 and gave the company an "overweight" rating in a report on Friday, February 28th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, Vir Biotechnology presently has a consensus rating of "Moderate Buy" and an average target price of $35.67.

Insider Buying and Selling

In related news, EVP Verneuil Vanina De sold 7,373 shares of the stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $9.14, for a total transaction of $67,389.22. Following the transaction, the executive vice president now directly owns 79,460 shares in the company, valued at approximately $726,264.40. This represents a 8.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Backer Marianne De sold 79,712 shares of the company's stock in a transaction dated Thursday, April 3rd. The shares were sold at an average price of $5.95, for a total transaction of $474,286.40. Following the transaction, the chief executive officer now directly owns 769,505 shares of the company's stock, valued at approximately $4,578,554.75. This represents a 9.39 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 99,611 shares of company stock worth $663,525 in the last ninety days. 15.60% of the stock is owned by corporate insiders.

Vir Biotechnology Trading Down 0.7 %

Vir Biotechnology stock traded down $0.04 during trading on Monday, hitting $5.49. The company had a trading volume of 65,625 shares, compared to its average volume of 1,335,334. The stock has a market cap of $752.92 million, a price-to-earnings ratio of -1.40 and a beta of 1.14. Vir Biotechnology, Inc. has a 1-year low of $4.95 and a 1-year high of $14.45. The company's 50 day simple moving average is $7.68 and its 200-day simple moving average is $8.18.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.09. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The company had revenue of $12.37 million during the quarter, compared to analysts' expectations of $8.14 million. As a group, analysts forecast that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).